1 pahu (10 Vials)
| Loaʻa: | |
|---|---|
| Ka nui: | |
▎ He aha ka Teriparatid?
ʻO ka Teriparatid he mea hoʻohālikelike homona parathyroid kanaka (PTH) hou i haku ʻia me nā 34 amino acids mua o ka hormone parathyroid kanaka. Hoʻoponopono ia i ka metabolism iwi ma ka hoʻohālike ʻana i nā hana physiological o ka hormone parathyroid endogenous. ʻO Teriparatid ka lāʻau anabolic synthetic mua i ʻae ʻia no ka osteoporosis koʻikoʻi. Hōʻike kona ʻano i ka homology kiʻekiʻe me ka PTH endogenous, hiki i ka hoʻāla ʻana o ka mea loaʻa PTH e hoʻololi i ka hana metabolic osteoclast.
▎ Teriparatid Kūlana
Puna: PubChem |
Kaʻina: SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF Huihui Molekala: C 181H 291N 55O 51S2 Kaumaha Molekala: 4118 g/mol Helu CAS: 52232-67-4 PubChem CID:16133850 Synonyms: Teriparatida; Teriparatidum; 1-34-PTH kanaka |
▎ Teriparatid Ke noiʻi
He aha ka wehewehe ʻana o Teriparatid?
ʻO ka Teriparatid he mea hoʻohālikelike homona parathyroid kanaka (PTH) hou i haku ʻia me nā 34 amino acids mua o ka hormone parathyroid kanaka. Hoʻoponopono ia i ka metabolism iwi ma ka hoʻohālike ʻana i nā hana physiological o ka hormone parathyroid endogenous. ʻO Teriparatid ka lāʻau anabolic synthetic mua i ʻae ʻia no ka osteoporosis koʻikoʻi. Hōʻike kona ʻano i ka homology kiʻekiʻe me ka PTH endogenous, hiki i ka hoʻāla ʻana o ka mea loaʻa PTH e hoʻololi i ka hana metabolic osteoclast.
He aha ke ʻano o ka hana no Teriparatid?
Nā hopena ma nā osteoblasts:
Hoʻoulu i ka hoʻonui osteoblast: Hoʻoulu ka Teriparatid i ka hoʻonui ʻana o nā cell precursor osteoblast, e hoʻonui ana i nā helu osteoblast. Ma nā haʻawina holoholona, ʻoi aku ka wikiwiki o ka hoʻohana ʻana i ka teriparatide i ka hoʻonui ʻana o nā pūnaewele mesenchymal stem hiki ke hoʻokaʻawale i nā osteoblast i loko o ka iwi iwi. ʻO kēia ka mea i hiki ai i nā cell hou ke hoʻokaʻawale i nā osteoblast oʻo, e hāʻawi ana i kahi lako kelepona nui no ka hana iwi. Ua hōʻike ʻia nā hoʻokolohua moʻomeheu in vitro cell i ʻoi aku ka kiʻekiʻe o ka māhele o nā cell osteoblast precursor i ka hui Teriparatid-treated ma mua o ka pūʻulu mana, e hōʻike ana ʻo Teriparatid e hoʻolaha pololei i ka hoʻonui ʻana o nā cell osteoblast precursor [1,2].
Hoʻonui i ka Osteoblast Activity: ʻAʻole hoʻonui ka Teriparatid i nā helu osteoblast akā hoʻokiʻekiʻe hoʻi i kā lākou hana. Hoʻoponopono ia i ka hōʻike ʻana o nā genes e pili ana i ka synthesis iwi matrix i nā osteoblasts, e like me kēlā me kēia collagen type I collagen a me osteocalcin, e hōʻike ana i ka piʻi nui ʻana o nā pae hōʻike. ʻO ke ʻano kolagen ʻano I, ka mea hoʻokalakupua mua o ka iwi iwi, kōkua i ka hoʻokumu ʻana i kahi papa hana matrix ʻoi aku ka ikaika ma o ka hoʻonui ʻana i ka synthesis. He kuleana koʻikoʻi ka Osteocalcin i ka mineralization iwi ma o ka hoʻolaha ʻana i ka waiho ʻana o ka calcium ion i loko o ka matrix, a laila e hoʻonui ai i ka mineralization iwi. Ma o kēia mau hana, hoʻohui a huna ʻia nā osteoblast i ka iwi matrix me ka maikaʻi loa, e hoʻomaʻamaʻa i ka hana iwi hou [2,3].
Kāohi i ka osteocyte apoptosis: Ma lalo o nā kūlana physiological maʻamau, loaʻa nā osteocytes i ka apoptosis ma hope o ka hoʻopau ʻana i nā hana hana iwi kikoʻī. Hoʻopau ʻo Teriparatid i kēia kaʻina apoptotic, e hoʻolōʻihi i ke ola osteocyte. Hoʻoikaika ʻo Teriparatid i nā ala hōʻailona kelepona pili, e like me ke ala PI3K/Akt. Ma ka hoʻouluʻana, hoʻopau kēia alahele i ka'ōlelo o nā protein pili i ka apoptosis, e hiki ai i nā osteoblasts ke hoʻomau i kā lākou mau hana iwi a mālama i ka hoʻomau a me ka paʻa o ka hana iwi [1,3].
Nā hopena ma nā Osteoclasts: He paʻakikī nā hopena o Teriparatid ma nā osteoclast. I ka wā o ka hoʻopaʻa ʻana, hoʻololi ia i nā osteoclasts ma o nā ʻano hana ʻole. Hoʻoikaika ia i ka hoʻoheheʻe osteoblast o osteoprotegerin (OPG), he cytokine e hoʻopaʻa hoʻokūkū i ka mea hoʻoiho o ka mea nukle κB ligand (RANKL). ʻO RANKL kahi mea hoʻoponopono koʻikoʻi o ka ʻokoʻa osteoclast a me ka hoʻāla ʻana. Ke hoʻopaʻa ʻo OPG i ka RANKL, ʻaʻole hiki i ka RANKL ke hoʻopaʻa i ka mea loaʻa RANK ma ka ʻili o nā cell precursor osteoclast, no laila ke keʻakeʻa nei i ka ʻokoʻa osteoclast a me ka maturation a me ka hōʻemi ʻana i ka resorption iwi. I nā poʻe maʻi osteoporosis, kahi i ʻoi aku ka nui o ka hoʻihoʻi ʻana o ka iwi ma mua o ke kūkulu ʻana e alakaʻi ana i ka nalowale o ka iwi, hoʻemi ka teriparatide i ka hana osteoclast ma o kēia ʻano hana. Hoʻihoʻi kēia i ke kaulike ma waena o ka resorption a me ka hoʻokumu ʻana, e hāpai ana i ka loaʻa ʻana o ka iwi [2,3].

Kiʻi 1 Nā kahua o ka hana no ka lāʻau mua o ka osteoporosis. ʻO Teriparatid, kahi ʻāpana recombinant o ka hormone parathyroid, hoʻoulu i ka hana iwi ma o ka hoʻonui ʻana i ka hana osteoblast a, i ka liʻiliʻi liʻiliʻi, ke keʻakeʻa nei i ka hōʻiliʻili osteoclast [4].
ʻO ka hoʻololi ʻana i nā ala hōʻailona pili i ka iwi:
Alanui Hōʻailona Wnt/β-Catenin: He kuleana koʻikoʻi ke ala hōʻailona Wnt/β-catenin i ka ulu ʻana o ka iwi a me ka mālama ʻana i ka homeostasis iwi. Hoʻoulu ʻo Teriparatid i kēia ala, e hoʻoikaika ana i ka hōʻiliʻili intracellular a me ka translocation nuklea o β-catenin. Hoʻopili ʻo Nuclear β-catenin i nā kumu transcription e pili ana, e hoʻomaka ana i ka transcription o nā genes e pili ana i ka hoʻokumu ʻana o ka iwi a me ka hoʻonui ʻana i ka hōʻike ʻana o ka osteoblast-specific transcription factor Runx2. Hoʻoponopono hou ʻo Runx2 i ka ʻokoʻa a me ka hana o ka osteoblast, a laila e hoʻoikaika ai i ka hoʻokumu ʻana o ka iwi. ʻO ka hoʻouluʻana i kēia alahele e kāohi i ka hoʻokaʻawaleʻana o ka osteoblast i nā adipocytes, e hōʻoiaʻiʻo ana i ka hoʻokaʻawale nuiʻana o nā pūpū mesenchymal stem cell i ka iwi osteoblast, a laila e hoʻonui ai i ka iwi iwi [1,3].
PTH/PTHrP Receptor Signaling Pathway: Teriparatid, he analog o ka hormone parathyroid (PTH), hoʻohana mua i kona hopena ma ka hoʻopaʻa ʻana i ka mea loaʻa PTH/PTHrP. Ke hoʻopaʻa ʻia, hoʻāla ʻo Teriparatid i nā ala hōʻailona o lalo e like me ke ala cAMP/PKA a me ke ala PLC/PKC. ʻO ka hoʻouluʻana i kēia mau alahele e hoʻoponopono i ka hana osteoblast a me ka osteoclast, e hoʻoikaika i ka hana iwi. Hoʻonui ke ala cAMP/PKA i ka hōʻike ʻana i nā genes pili i ka osteoblast ma o ka hoʻololi ʻana i ka hana transcription factor, ʻoiai ke ala PLC/PKC e hoʻohuli i ka cytoskeletal reorganization a me ka motility cell, e pili ana i ka neʻe ʻana o ka osteoblast a me ka hana [2,5].
He aha nā mea hoʻohana o Teriparatid?
Lapaʻau Osteoporosis
Postmenopausal Osteoporosis: ʻO Teriparatid ka mea mua anabolic synthetic i ʻae ʻia no ka mālama ʻana i nā wahine postmenopausal me ka osteoporosis koʻikoʻi. Ma ka hoʻoulu ʻana i ka hoʻokumu ʻana o ka iwi, hoʻonui ia i ka nui o ka iwi, a laila e hōʻemi i ka pilikia o ka haki. I nā wahine postmenopausal, hoʻonui ka hoʻohana ʻana i ka teriparatide i kēlā me kēia lā i ka nui o ka iwi minerala, e hōʻemi ana i ka hopena o nā haʻihaʻi vertebral e 65% a me nā haʻihaʻi non-vertebral fragility e 53% i hoʻohālikelike ʻia me ka placebo. Ua hōʻike ʻia kahi meta-analysis o kēlā me kēia kanaka maʻi-level ikepili i ka 56% ka emi ʻana o ka hōʻemi ʻana o ka hip fracture i hoʻohālikelike ʻia me nā mana. Eia kekahi, i ka hoʻohālikelike ʻana i ka risedronate, ua hoʻemi ʻo Teriparatid i ka pilikia o ka vertebral a me nā haʻihaʻi lapaʻau hou e 56% a me 52%, i kēlā me kēia, i nā wahine me ka osteoporosis koʻikoʻi [3,6,7].
Male Osteoporosis: Ua ʻae ʻia no ka mālama ʻana i ka osteoporosis kāne. Quattrocchi E et al. Ua hōʻike ʻo ia i nā maʻi osteoporosis kāne, Teriparatid (20μg a me 40μg i kēlā me kēia lā injections) i hoʻonui nui ʻia i ka nui o ka iwi lumbar spine mineral density: 5.9% i ka hui 20μg a me 9.0% i ka hui 40μg (ʻelua P <0.001). Ma ka ʻāʻī femoral, hoʻonui ʻia ka iwi iwi e 1.5% i ka hui 20μg (P = 0.021) a me 0.9% i ka hui 40μg (P <0.001) [7].
Glucocorticoid-Associated Osteoporosis: Hoʻohana pū ʻia ʻo Teriparatid e mālama i ka osteoporosis i hoʻokomo ʻia i ka glucocorticoid i nā kāne a me nā wahine maʻi me nā haʻihaʻi, e kōkua ana i kēia mau maʻi e hoʻonui i ka iwi iwi a hoʻemi i ka nalo iwi a me ka haʻihaʻi pili i ka hoʻohana ʻana i ka glucocorticoid [8].
Kākoʻo Ho'ōla Haʻihaʻi: No nā poʻe maʻi haʻihaʻi, he mea koʻikoʻi ka hoʻonui ʻana i ka hoʻokumu ʻana o ka iwi ma ke kahua haʻi no ka hoʻoponopono ʻana, hiki ke hoʻokō i kahi hana teriparatide. Ua aʻo ʻia i loko o nā ʻano holoholona ʻelua a me nā mea maʻi ma ke ʻano he mea hiki ke hoʻoikaika i ka hoʻōla ʻana i ka haʻihaʻi. ʻOiai e pono ana ka noiʻi hou ʻana, hōʻike nā ʻimi i kēia manawa i kona hiki ke hoʻoikaika i ka ho'ōla ʻana [3].
ʻO ka hoʻoponopono hou ʻana i ka iwi alveolar: Hōʻike nā haʻawina e pili ana i ka Teriparatid no ka hoʻōla hou ʻana o ka iwi alveolar i nā kūlana e like me ka iwi iwi necrosis, periodontitis mau, ka osseointegration implant, a me ka neʻe ʻana o nā niho orthodontic, kahi e hoʻonui ai i ka hoʻokumu ʻana o ka iwi alveolar. Eia nō naʻe, pono nā hoʻokolohua hoʻokolohua kanaka hou e hōʻoia i kāna noi a me nā hopena ʻino ma waena o nā maʻi iwi waha [9].
Osteoporosis pili i ka hāpai ʻana a me ka lactation: I nā poʻe maʻi me ka osteoporosis pili i ka hāpai ʻana a me ka lactation (PLO), ʻo ka mālama ʻana me Teriparatid (20μg / lā) i hui pū ʻia me ka calcium a me ka vitamina D i hopena i ka piʻi nui ʻana o ka nui o ka iwi iwi iwi lumbar ma 12 a me 24 mau mahina i hoʻohālikelike ʻia me ka calcium a me ka vitamina D wale nō. I nā mahina 12, ʻo ka piʻi nui ʻana o ka nui o ka iwi iwi iwi lumbar he 20.9 ± 11.9% ma ka hui teriparatide me 6.2 ± 4.8% i ka pūʻulu mana (P <0.001). Ma nā mahina 24,ʻo ka piʻi nui o ka nui o ka mineral iwi iwi lumbar he 32.9 ± 13.4% i nā maʻi 7 i mālamaʻia me Teriparatid a me 12.2 ± 4.2% i nā maʻi hoʻomalu 6 (P = 0.001). ʻAʻole i loaʻa nā haʻihaʻi hou i ka wā o ka mālama ʻana [10].
Nā Hoʻohana Kūikawā: Ua hōʻike ʻia ʻo Teriparatid i nā noiʻi hihia no nā maʻi iwi kikoʻī, e like me ka hypoparathyroidism-associated osteodystrophy (ABD) me ka hypercalcemia. Ua hoʻomohala kekahi wahine maʻi dialysis 51 makahiki i ka hypercalcemia post-parathyroidectomy, i hōʻoia ʻia e ka biopsy iwi e like me ABD. Ma hope o 12 mau mahina o ka mālama ʻana iā Teriparatid, ua hoʻoponopono ʻia nā pae calcium serum, e hōʻike ana i ka hihia mua i kākau ʻia o Teriparatid e hoʻonā i ka hypercalcemia pili i ka ABD [11].
Ka hopena
Hoʻohana maikaʻi ʻo Teriparatid no ka osteoporosis koʻikoʻi me ka nui o ka haki. Hōʻike ʻia ia no nā poʻe maʻi me ka mōʻaukala o nā haʻihaʻi osteoporotic he nui, haʻahaʻa haʻahaʻa haʻahaʻa haʻahaʻa haʻahaʻa haʻahaʻa haʻahaʻa haʻahaʻa o ka pane ʻana i nā lāʻau osteoporosis maʻamau.
No ka mea kakau
ʻO nā mea i ʻōlelo ʻia ma luna nei ua noiʻi ʻia, hoʻoponopono ʻia a hōʻuluʻulu ʻia e Cocer Peptides.
Mea kākau moʻolelo ʻepekema
He mea noiʻi ʻo Susan V. Bukata ma ke Kulanui o Rochester School of Medicine and Dentistry, ʻoihana loea i nā maʻi orthopedic a me nā maʻi musculoskeletal. Ua kākau pū ʻo ia i nā puke he nui e pili ana i ka biology iwi, ka ho'ōla ʻana i ka haʻihaʻi, a me nā noi lapaʻau o nā mea anabolic e like me teriparatide i ka hana orthopedic. Ua kōkua kāna hana i ka hoʻomaopopo ʻana i nā hoʻolālā therapeutic no ka hoʻomaikaʻi ʻana i ka hoʻoponopono ʻana i ka iwi a me ka hana hou ʻana. Ua helu ʻia ʻo Susan V. Bukata ma ka ʻōlelo kuhikuhi [1].
▎ Nā ʻōlelo pili
[1] Bukata SV, Puzas JE. ʻO ka hoʻohana ʻana i ka teriparatide. Nā Hōʻike Osteoporosis o kēia manawa 2010; 8(1): 28-33.DOI: 10.1007/s11914-010-0006-3.
[2] Hasegawa T, Miyamoto Y, Yamamoto T, Amizuka N. [Ka hana anabolic o teriparatide i nā maʻi osteoporotic]. Nihon Yakurigaku Zasshi 2019; 153(1): 16-21.DOI: 10.1254/fpj.153.16.
[3] Marin F, Ma YL. Osteoporotic Fracture a me Systemic Skeletal Disorders: Mechanism, Assessment, and Treatment. In: Takahashi HE, Burr DB, Yamamoto N, eds. Teriparatid. Singapore: Springer Singapore; 2022: 339-359.DOI: 10.1007/978-981-16-5613-2_22.
[4] Hanley D, Adachi J, Bell A, Brown V. Denosumab: Mechanism o ka hana a me nā hopena lapaʻau. International Journal of Clinical Practice 2012; 66.DOI: 10.1111/ijcp.12022.
[5] Kim S. Mechanism a me ka pono o ka hormone parathyroid i ka osteoporosis. Nūpepa o ka Hui Lapaʻau Korea 2022; 65: 361-365.DOI: 10.5124/jkma.2022.65.6.361.
[6] Stroup JS, Kane MP, Abu-Baker A. Teriparatid i ka mālama ʻana i ka osteoporosis. American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists 2008; 65 6: 532-539. https://api.semanticscholar.org/CorpusID:207290777.
[7] Quattrocchi E, Kourlas H. Teriparatid: he loiloi. ʻO nā lāʻau lapaʻau lapaʻau 2004; 26 6: 841-854. https://api.semanticscholar.org/CorpusID:20011673.
[8] Minisola S, Cipriani C, Grotta GD, et al. Hōʻike hou i ka palekana a me ka maikaʻi o ka teriparatide i ka mālama ʻana i ka osteoporosis. ʻO nā holomua lapaʻau i ka maʻi Musculoskeletal 2019; DOI: 10.1177/1759720X19877994.
[9] ʻO Agnihotri R, Gaur S. Nā noi o Teriparatid no ka hoʻoponopono hou ʻana i ka iwi Alveolar: He Manaʻo Systematic. Nūpepa o ka International Society of Preventive and Community Dentistry 2021; 11(6): 639-643.DOI: 10.4103/jispcd.JISPCD_169_21.
[10] Lampropoulou-Adamidou K, Trovas G, Triantafyllopoulos IK, et al. ʻO ka Lapaʻau Teriparatid i nā maʻi me ka Osteoporosis pili i ka hāpai ʻana a me ka lactation. Hui Pūʻulu Calcified 2021; 109(5): 554-562.DOI: 10.1007/s00223-021-00871-y.
[11] Peugh J, Khalil A, Chan MR, Hansen KE. ʻO ka Lapaʻau Teriparatid no ka Hypercalcemia i pili me ka maʻi iwi Adynamic. Jbmr Plus 2019; 3(7): e10176.DOI: 10.1002/jbm4.10176.
ʻO nā ʻatikala a me nā ʻike huahana i hāʻawi ʻia ma kēia pūnaewele pūnaewele wale nō no ka hoʻolaha ʻana i ka ʻike a me nā kumu hoʻonaʻauao.
ʻO nā huahana i hāʻawi ʻia ma kēia pūnaewele i manaʻo wale ʻia no ka noiʻi in vitro. Hana ʻia ka noiʻi in vitro (Latin: *i ke aniani*, ʻo ia hoʻi i ka ipu aniani) ma waho o ke kino kanaka. ʻAʻole kēia mau huahana he lāʻau lapaʻau, ʻaʻole i ʻae ʻia e ka US Food and Drug Administration (FDA), a ʻaʻole pono e hoʻohana ʻia no ka pale ʻana, mālama, a hoʻōla paha i kekahi maʻi olakino, maʻi, a maʻi paha. Ua pāpā loa ʻia e ke kānāwai ke hoʻokomo i kēia mau huahana i loko o ke kino kanaka a holoholona paha ma kekahi ʻano.